Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 7687 results

  1. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    Diagnostics guidance
    Published
    31 July 2024
    View recommendations

    Sections for DG59

  4. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    Awaiting development [GID-TA11643] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]

    Awaiting development [GID-TA11638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

    In development [GID-TA10611] Expected publication date: 18 December 2024

    Technology appraisal guidance
    In development

  8. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

    In development [GID-TA11512] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  9. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  10. Urinary Tract Infection (recurrent): antimicrobial prescribing

    In development [GID-NG10422] Expected publication date: 12 December 2024

    NICE guideline
    In development

  11. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082

    In development [GID-TA10969] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development [GID-DG10083] Expected publication date: 17 July 2025

    Diagnostics guidance
    In development

  14. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  15. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development